24/7 Market News- Cingulate Receives European Patent for Its CTx-1301 ADHD Treatment
DENVER, Colo., Aug 15, 2024 (247marketnews.com)- Cingulate Inc. (NASDAQ: CING) reported receiving European patent, EP Patent No. 3261625, for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), which was granted on August 14, 2024. The patent covers up to 30 European territories, including the United Kingdom.
Cingulate’s Chairman and CEO, Shane J. Schaffer, commented, “The granting of this patent is another meaningful milestone as Cingulate seeks to expand its reach beyond the United States and make a positive impact on the growing ADHD markets in Europe and other territories abroad. We look forward to obtaining additional patents in the near-term as we continue to showcase the clinical success of CTx-1301 and move closer to filing a new drug application with the FDA.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (CING)
- Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)
- 24/7 Market News Snapshot 20 May, 2025 – Cingulate Inc. Common Stock (NASDAQ:CING)
- Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
- FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
- 24/7 Market News Snapshot 14 May, 2025 – Cingulate Inc. Common Stock (NASDAQ:CING)